BTBD10 and hepatocellular carcinoma: Therefore, patients with low BTBD10 expression are more suitable for targeted drugs combined with ferroptosis-related therapy, while patients with high BTBD10 expression are more suitable for multiple targeted drugs combination or combined m6A-related therapy, which may bring hope for the treatment of HCC patients.